Hudson Bay Capital Management LP Sells 5,000 Shares of Merck & Co., Inc. (NYSE:MRK)

Hudson Bay Capital Management LP lessened its holdings in Merck & Co., Inc. (NYSE:MRK) by 25.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 15,000 shares of the company’s stock after selling 5,000 shares during the quarter. Hudson Bay Capital Management LP’s holdings in Merck & Co., Inc. were worth $1,227,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of MRK. Pinnacle Bank raised its holdings in Merck & Co., Inc. by 4.9% during the 4th quarter. Pinnacle Bank now owns 2,652 shares of the company’s stock worth $217,000 after purchasing an additional 123 shares during the last quarter. YHB Investment Advisors Inc. raised its holdings in Merck & Co., Inc. by 1.0% during the 4th quarter. YHB Investment Advisors Inc. now owns 13,112 shares of the company’s stock worth $1,073,000 after purchasing an additional 127 shares during the last quarter. Janney Capital Management LLC raised its holdings in Merck & Co., Inc. by 0.5% during the 4th quarter. Janney Capital Management LLC now owns 28,508 shares of the company’s stock worth $2,332,000 after purchasing an additional 130 shares during the last quarter. Sawyer & Company Inc raised its holdings in Merck & Co., Inc. by 0.5% during the 4th quarter. Sawyer & Company Inc now owns 24,744 shares of the company’s stock worth $2,024,000 after purchasing an additional 130 shares during the last quarter. Finally, KCS Wealth Advisory raised its holdings in Merck & Co., Inc. by 1.1% during the 4th quarter. KCS Wealth Advisory now owns 11,916 shares of the company’s stock worth $975,000 after purchasing an additional 134 shares during the last quarter. Institutional investors and hedge funds own 72.86% of the company’s stock.

NYSE MRK opened at $76.12 on Thursday. The stock has a market capitalization of $192.61 billion, a price-to-earnings ratio of 16.84, a PEG ratio of 1.89 and a beta of 0.43. Merck & Co., Inc. has a one year low of $71.71 and a one year high of $87.80. The company has a debt-to-equity ratio of 0.90, a current ratio of 1.30 and a quick ratio of 1.00. The business’s fifty day moving average is $75.36 and its 200-day moving average is $79.05.

Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings data on Wednesday, February 3rd. The company reported $1.32 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $1.38 by ($0.06). Merck & Co., Inc. had a net margin of 24.33% and a return on equity of 53.83%. The firm had revenue of $12.51 billion during the quarter, compared to the consensus estimate of $12.65 billion. During the same quarter in the prior year, the firm posted $1.16 earnings per share. The company’s revenue was up 5.4% on a year-over-year basis. Research analysts expect that Merck & Co., Inc. will post 5.9 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which was paid on Wednesday, April 7th. Shareholders of record on Monday, March 15th were issued a dividend of $0.65 per share. This represents a $2.60 dividend on an annualized basis and a yield of 3.42%. The ex-dividend date was Friday, March 12th. Merck & Co., Inc.’s payout ratio is presently 50.10%.

Separately, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Merck & Co., Inc. in a research report on Friday, February 5th. Two analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $95.92.

Merck & Co., Inc. Profile

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as and vaccine products.

Featured Article: Fundamental Analysis and Individual Investors

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.